Clinical Survey of the Medtronic Liberant Thrombectomy System for Removing Blood Clots in Peripheral Arteries and Veins

What this Trial Is About

This research aims to collect first-in-human clinical data on the Liberant Thrombectomy System, a device designed to remove fresh, soft emboli or thrombi from the vessels in the peripheral arterial and venous systems. The study will evaluate the safety and performance of the device during routine use by healthcare professionals. It focuses on cases involving patients with various conditions such as venous embolism, deep vein thrombosis DVT, and acute limb ischemia. The study is a multicenter, prospective survey where healthcare professionals document their individual experiences using the Liberant device according to its approved labeling. Each case is recorded within 72 hours of the procedure to capture any periprocedural incidents and assess device performance. At least 50 case reports from at least 10 healthcare professionals will be collected and analyzed, with no patient follow-up involved. Participants in this study are patients treated with the Liberant device as part of routine care, with data collected only once per case. Healthcare professionals will provide detailed reports on procedure outcomes and any serious adverse events. The study team will review measures such as the rate of device-related serious adverse events, technical success, and procedural success. The total study duration extends until October 2026, with no additional patient monitoring beyond the initial procedure documentation.

Case-Specific Health Care Professional Clinical Survey of Liberant™ Thrombectomy System